VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

B. bovis GST-12D3
Vaccine Information
  • Vaccine Name: B. bovis GST-12D3
  • Vaccine Ontology ID: VO_0011375
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: B. bovis T2Bo 12D3
  • 12D3 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The 12D3 protective antigen was cloned and expressed as a glutathione-S-transferase (GST) fusion protein (Wright et al., 1992).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Vector: pGEX
  • Immunization Route: Intramuscular injection (i.m.)
References
Wright et al., 1992: Wright IG, Casu R, Commins MA, Dalrymple BP, Gale KR, Goodger BV, Riddles PW, Waltisbuhl DJ, Abetz I, Berrie DA. The development of a recombinant Babesia vaccine. Veterinary parasitology. 1992; 44(1-2); 3-13. [PubMed: 1441189].
E. histolytica CEL-170/4 protein vaccine
Vaccine Information
  • Vaccine Name: E. histolytica CEL-170/4 protein vaccine
  • Vaccine Ontology ID: VO_0011414
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: E. histolytica alactose-specific adherence lectin heavy subunit (CEL-170/4)
  • CEL-170/4 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The galactose-specific lectin has been purified from a pathogenic strain of E. histolytica by monoclonal antibody affinity chromatography (Petri and Ravdin, 1991).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
Petri and Ravdin, 1991: Petri WA Jr, Ravdin JI. Protection of gerbils from amebic liver abscess by immunization with the galactose-specific adherence lectin of Entamoeba histolytica. Infection and immunity. 1991; 59(1); 97-9101. [PubMed: 1987067].
E. histolytica Eh29 protein vaccine
Vaccine Information
  • Vaccine Name: E. histolytica Eh29 protein vaccine
  • Vaccine Ontology ID: VO_0011450
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: E. histolytica alkyl hydroperoxide reductase Eh29
  • gEh29 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The full coding region of the gEh29 gene which encodes Eh29 (GenBank Accession No. X70996.1) was amplified by PCR and the 0.7 Kb amplicon was cloned into the expression vector pRSET-A (Invitrogen, CA, USA) following standard methods. After transformation into Escherichia coli BL21 (DE3) pLysS (Stratagene, CA, USA) positive clones were selected on ampicillin and chloramphenicol and were induced for expression of amino-terminal His-tagged Eh29 by incubation with 2 mM IPTG (Carrero et al., 2010).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
Carrero et al., 2010: Carrero JC, Contreras-Rojas A, Sánchez-Hernández B, Petrosyan P, Bobes RJ, Ortiz-Ortiz L, Laclette JP. Protection against murine intestinal amoebiasis induced by oral immunization with the 29kDa antigen of Entamoeba histolytica and cholera toxin. Experimental parasitology. 2010; ; . [PubMed: 20303954].
E. histolytica Gal/GalNAc lectin protein vaccine
Vaccine Information
  • Vaccine Name: E. histolytica Gal/GalNAc lectin protein vaccine
  • Vaccine Ontology ID: VO_0011451
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: E. histolyica Gal/GalNAc lectin
  • Gal/GalNAc lectin gene engineering:
    • Type: Recombinant protein preparation
    • Description: The native E. histolytica Gal/GalNAc lectin was purified from strain HM1:IMSS trophozoites grown under axenic conditions as described previously [5]. A large fragment of the Gal/GalNAc lectin heavy subunit spanning amino acids 578–1154 (“LecA”) was cloned into a pRSET-A vector (Invitrogen, Carlsbad, CA) with a kanamycin resistance gene and expressed in E. coli. The E. coli cells were lyzed by sonication and isolated inclusion bodies were denatured in inclusion body solubilization reagent (Pierce, Rockford, IL) (Houpt et al., 2004).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
Houpt et al., 2004: Houpt E, Barroso L, Lockhart L, Wright R, Cramer C, Lyerly D, Petri WA. Prevention of intestinal amebiasis by vaccination with the Entamoeba histolytica Gal/GalNac lectin. Vaccine. 2004; 22(5-6); 611-617. [PubMed: 14741152].
E. maxima Gam82 protein vaccine
Vaccine Information
  • Vaccine Name: E. maxima Gam82 protein vaccine
  • Vaccine Ontology ID: VO_0011467
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: E. maxima 82 kDa gametocyte antigen (Gam82)
  • gam82 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The Gam82 coding sequence was amplified by PCR using Proof Start DNA polymerase (Qiagen, Valencia, CA). Amplicons were cloned into the pET28a (+) plasmid vector (Novagen/EMD Chemicals, Gibbstown, NJ) downstream from an NH2-terminal His6 epitope tag, plasmid clones were verified by sequence analysis, and used to transform competent Escherichia coli BL21 Star (Invitrogen). Eluted protein fractions were visualized on 10% SDS-acrylamide gels stained with Coomassie brilliant blue and on Western blots probed with horseradish peroxidase-conjugated anti-His monoclonal antibody (1:3000; Qiagen), and stored at −20 °C (Jang et al., 2010).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0000139
    • Description: Freund's complete adjuvant (FCA)
  • Immunization Route: Intramuscular injection (i.m.)
References
Jang et al., 2010: Jang SI, Lillehoj HS, Lee SH, Lee KW, Park MS, Cha SR, Lillehoj EP, Subramanian BM, Sriraman R, Srinivasan VA. Eimeria maxima recombinant Gam82 gametocyte antigen vaccine protects against coccidiosis and augments humoral and cell-mediated immunity. Vaccine. 2010; 28(17); 2980-2985. [PubMed: 20178868].
E. tenella GX3262 protein vaccine
Vaccine Information
  • Vaccine Name: E. tenella GX3262 protein vaccine
  • Vaccine Ontology ID: VO_0011470
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: E. tenella sporozoite antigen GX3262
  • GX3262 gene engineering:
    • Type: Recombinant protein preparation
    • Description: To produce the 3-galactosidase-GX3262 fusion protein (Pgal-GX3262), recombinant E. coli cells. grown overnight in Luria-Bertani broth with ampicillin and induced with IPTG, were lysed by sonication and centrifuged, and the insoluble cell pellet was washed extensively with PBS (Miller et al., 1989).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Subcutaneous injection
References
Miller et al., 1989: Miller GA, Bhogal BS, McCandliss R, Strausberg RL, Jessee EJ, Anderson AC, Fuchs CK, Nagle J, Likel MH, Strasser JM. Characterization and vaccine potential of a novel recombinant coccidial antigen. Infection and immunity. 1989; 57(7); 2014-2020. [PubMed: 2659532].
FMP1/AS02A
Vaccine Information
  • Vaccine Name: FMP1/AS02A
  • Vaccine Ontology ID: VO_0000777
  • Type: Subunit vaccine
  • Antigen: Apical membrane antigen 1 (AMA-1) is an asexual blood stage antigen. AMA-1 is considered to be an important candidate malaria vaccine antigen (Morais et al., 2006; Polhemus et al., 2007).
  • AMA1 from P. falciparum 3D7 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001264
    • Description: The Plasmodium falciparum vaccine candidate FMP2.1/AS02A , a recombinant E coli-expressed protein based upon the apical membrane antigen-1 (AMA-1 ) of the 3D7 clone formulated with the AS02A adjuvant(Polhemus et al., 2007)
  • Preparation: FMP2.1 antigen represents amino acids #83-531 of the P. falciparum (clone 3D7) AMA-1 protein. Just prior to immunization, the lyophilized FMP2.1 protein was mixed with AS02A such that approximately 8, 20 or 40 μg of FMP2.1 was delivered in a final volume of 0.5 mL of AS02A (Polhemus et al., 2007).
References
Morais et al., 2006: Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM. Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. The American journal of tropical medicine and hygiene. 2006 Oct; 75(4); 582-7. [PubMed: 17038677].
Polhemus et al., 2007: Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2007 May 22; 25(21); 4203-12. [PubMed: 17442466].
L. amazonensis CP Protein Vaccine
Vaccine Information
  • Vaccine Name: L. amazonensis CP Protein Vaccine
  • Vaccine Ontology ID: VO_0004199
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24 (Fedeli et al., 2010).
  • CP cysteine proteinase gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
References
Fedeli et al., 2010: Fedeli CE, Ferreira JH, Mussalem JS, Longo-Maugéri IM, Gentil LG, dos Santos MR, Katz S, Barbiéri CL. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis. Experimental parasitology. 2010; 124(2); 153-158. [PubMed: 19735658].
L. amazonensis M2 protein vaccine
Vaccine Information
  • Vaccine Name: L. amazonensis M2 protein vaccine
  • Vaccine Ontology ID: VO_0011355
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: L. amazonensis M2
  • M2 gene engineering:
    • Type: Recombinant protein preparation
    • Description: M-2, a 46-kDa promastigote-specific glycoprotein was isolated. The protein was further purified by removal of detergent with an anionexchange column(Champsi and McMahon-Pratt, 1988).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
Champsi and McMahon-Pratt, 1988: Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection and immunity. 1988; 56(12); 3272-3279. [PubMed: 3182080].
L. donovani Beta-tubulin Protein Vaccine
Vaccine Information
References
Bhowmick and Ali, 2009: Bhowmick S, Ali N. Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis. PloS one. 2009; 4(6); e5820. [PubMed: 19503834].
L. donovani gp63 Protein Vaccine
Vaccine Information
  • Vaccine Name: L. donovani gp63 Protein Vaccine
  • Vaccine Ontology ID: VO_0011532
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: gp63
  • mspC gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
 
L. donovani GRP-78 Protein Vaccine
Vaccine Information
References
Nagill and Kaur, 2010: Nagill R, Kaur S. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis. Vaccine. 2010; 28(23); 4002-4012. [PubMed: 20093205].
L. donovani HASPB1 Protein Vaccine
Vaccine Information
  • Vaccine Name: L. donovani HASPB1 Protein Vaccine
  • Vaccine Ontology ID: VO_0004067
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: Recombinant hydrophilic acylated surface protein B1 (HASPB1) (Stäger et al., 2000).
  • HASPB1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Subcutaneous injection
References
Stäger et al., 2000: Stäger S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(12); 7064-7071. [PubMed: 11120835].
L. donovani LD31 Protein Vaccine
Vaccine Information
References
 
L. donovani ORFF Protein Vaccine
Vaccine Information
  • Vaccine Name: L. donovani ORFF Protein Vaccine
  • Vaccine Ontology ID: VO_0011539
  • Type: Subunit vaccine
  • Status: Research
  • ORFF gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001147
    • Description: An expression plasmid encoding both p35 and p40 subunits of IL-12 was used as an adjuvant (Tewary et al., 2006).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
L. donovani Recombinant LdγGCS in NIV system Vaccine
Vaccine Information
References
Henriquez et al., 2010: Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. The Journal of parasitology. 2010; 96(5); 929-936. [PubMed: 20950100].
L. infantum H1 protein vaccine
Vaccine Information
  • Vaccine Name: L. infantum H1 protein vaccine
  • Vaccine Ontology ID: VO_0011350
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: L. infantum histone H1
  • H1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The histone H1 and HASPB1 proteins were purified from endotoxins under pyrogenic free conditions in 1× PBS on a Superose 12 column (Amersham Biosciences) (Moreno et al., 2007).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001268
    • Description: Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC)
  • Immunization Route: Intradermal injection (i.d.)
References
Moreno et al., 2007: Moreno J, Nieto J, Masina S, Cañavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine. 2007; 25(29); 5290-5300. [PubMed: 17576026].
L. infantum HASPB1 protein vaccine
Vaccine Information
  • Vaccine Name: L. infantum HASPB1 protein vaccine
  • Vaccine Ontology ID: VO_0011351
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: L. infantum HASPB1
  • HASPB1 gene engineering:
    • Type: Recombinant protein preparation
    • Description: The L. infantum histone H1 was cloned into the pGEX-KG vector (Amersham Biosciences), expressed in Escherichia coli and purified using GST affinity resin (Amersham Biosciences) (Moreno et al., 2007).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001268
    • Description: Montanide™ ISA 720 (70% formulation, according to manufacturer's instructions, SEPPIC)
  • Immunization Route: Intradermal injection (i.d.)
References
Moreno et al., 2007: Moreno J, Nieto J, Masina S, Cañavate C, Cruz I, Chicharro C, Carrillo E, Napp S, Reymond C, Kaye PM, Smith DF, Fasel N, Alvar J. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine. 2007; 25(29); 5290-5300. [PubMed: 17576026].
L. infantum SMT Protein Vaccine
Vaccine Information
  • Vaccine Name: L. infantum SMT Protein Vaccine
  • Vaccine Ontology ID: VO_0004066
  • Type: Subunit vaccine
  • Status: Research
  • SMT gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
References
 
L. major H1 Protein Vaccine
Vaccine Information
References
Solioz et al., 1999: Solioz N, Blum-Tirouvanziam U, Jacquet R, Rafati S, Corradin G, Mauël J, Fasel N. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 1999; 18(9-10); 850-859. [PubMed: 10580198].
L. major H2B Protein Vaccine
Vaccine Information
  • Vaccine Name: L. major H2B Protein Vaccine
  • Vaccine Ontology ID: VO_0004045
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: The divergent amino-terminal region of H2B (Chenik et al., 2006).
  • H2B gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Subcutaneous injection
  • Description: An L. major subunit vaccine that is made of H2B protein and CpG adjuvant.
References
Chenik et al., 2006: Chenik M, Louzir H, Ksontini H, Dilou A, Abdmouleh I, Dellagi K. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major. Vaccine. 2006; 24(14); 2521-2529. [PubMed: 16417957].
L. major PSA-2 Protein Vaccine
Vaccine Information
  • Vaccine Name: L. major PSA-2 Protein Vaccine
  • Vaccine Ontology ID: VO_0004044
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • PSA-2 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
 
LEISH-F1+MPL-SE
Vaccine Information
  • Vaccine Name: LEISH-F1+MPL-SE
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: human
  • Antigen: LEISH-F1: a polyprotein composed of these three priority candidate antigens (LmSTI1, TSA, LeIF) fused in tandem, Leish-111f(Coler et al., 2002)
  • LeIF gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • TSA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • LmSTI1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
  • Description: A Leishmaniasis subunit vaccine made of LEISH-F1+MPL-SE (Nascimento et al., 2010)
References
 
LEISH-F1+MPL-SE vaccine
Vaccine Information
  • Vaccine Name: LEISH-F1+MPL-SE vaccine
  • Vaccine Ontology ID: VO_0004266
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Antigen: Recombinant Leishmania polyprotein LEISH-F1 (formerly known as Leish-111f) antigen. The antigen component of the vaccine includes three proteins derived from L. major and conserved across various Leishmania species, including L. donovani; L. chagasi, which causes New World VL; and L. braziliensis, which causes both CL and mucosal leishmaniasis (ML) in the New World. The three proteins are: Leishmania elongation initiation factor (LeIF), thiol-specific antioxidant (TSA), and Leishmania major stress-inducible protein 1 (LmSTI1) (Chakravarty et al., 2011).
  • Adjuvant:
  • Immunization Route: subcutaneous injection
References
Chakravarty et al., 2011: Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011; 29(19); 3531-3537. [PubMed: 21414377].
MSP3-LSP with aluminium hydroxide
Vaccine Information
  • Vaccine Name: MSP3-LSP with aluminium hydroxide
  • Vaccine Ontology ID: VO_0000773
  • Type: Subunit vaccine
  • Antigen: The merozoite surface protein-3 long synthetic peptide (MSP3-LSP) comprises the amino acid sequence 186-276 of the Plasmodium falciparum protein MSP3 (Sirima et al., 2007). The C-terminal conserved region of Plasmodium falciparum merozoite surface protein 3 (MSP3) is the trigger antigen of a protective immune response mediated by cytophilic antibodies (Audran et al., 2005).
  • Adjuvant:
    • VO ID: VO_0000127
    • Description: aluminium hydroxide (Sirima et al., 2007). In another phase I clinical trial study using MSP3-LSP, two adjuvants were used, including Montanide ISA 720 and aluminum hydroxide (Audran et al., 2005). However, it showed that it was unacceptably reactogenic when it was combined with Montanide (Audran et al., 2005).
  • Virulence: No.
References
Audran et al., 2005: Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and immunity. 2005 Dec; 73(12); 8017-26. [PubMed: 16299295].
Sirima et al., 2007: Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007 Mar 30; 25(14); 2723-32. [PubMed: 17280744].
N. caninum MIC10 and p24 protein vaccine
Vaccine Information
References
 
N. caninum NcMAG1 Protein Vaccine
Vaccine Information
  • Vaccine Name: N. caninum NcMAG1 Protein Vaccine
  • Vaccine Ontology ID: VO_0011564
  • Type: Subunit vaccine
  • Status: Research
  • MAG1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
 
N. caninum NcMIC1 Protein Vaccine
Vaccine Information
  • Vaccine Name: N. caninum NcMIC1 Protein Vaccine
  • Vaccine Ontology ID: VO_0011563
  • Type: Subunit vaccine
  • Status: Research
  • MIC1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
 
N. caninum NcPDI Protein Vaccine
Vaccine Information
  • Vaccine Name: N. caninum NcPDI Protein Vaccine
  • Vaccine Ontology ID: VO_0004009
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant NcPDI protein (Debache et al., 2010).
  • PDI gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0000143
    • Description: Cholera toxin adjuvant (Debache et al., 2010).
  • Immunization Route: Intranasally
References
Debache et al., 2010: Debache K, Guionaud C, Alaeddine F, Hemphill A. Intraperitoneal and intra-nasal vaccination of mice with three distinct recombinant Neospora caninum antigens results in differential effects with regard to protection against experimental challenge with Neospora caninum tachyzoites. Parasitology. 2010; 137(2); 229-240. [PubMed: 19835644].
P. berghei MSP1 Protein Vaccine
Vaccine Information
  • Vaccine Name: P. berghei MSP1 Protein Vaccine
  • Vaccine Ontology ID: VO_0004065
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant MSP1 (rPbMSP1)
  • MSP1 from P. berghei gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
 
P. chabaudi AMA1 Protein Vaccine
Vaccine Information
  • Vaccine Name: P. chabaudi AMA1 Protein Vaccine
  • Vaccine Ontology ID: VO_0004194
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant ectodomain of P. chabaudi adami (DS stain) AMA1 (denoted rAMA1B)
  • AMA-1 from P. chabaudi gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intraperitoneal injection (i.p.)
References
 
P. falciparum Hsp90 Protein Subunit Vaccine
Vaccine Information
References
 
P. falciparum LSA-3 Protein Vaccine
Vaccine Information
  • Vaccine Name: P. falciparum LSA-3 Protein Vaccine
  • Vaccine Ontology ID: VO_0004193
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant proteins GST-DG729, GST-NN and GST-PC were designed to cover 95% of the LSA-3 antigen and were used as a mixture (called LSA-3 GST-rec) (Daubersies et al., 2000).
  • LSA-3 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: subcutaneous injection
References
Daubersies et al., 2000: Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature medicine. 2000; 6(11); 1258-1263. [PubMed: 11062538].
P. falciparum MSA-2 subunit vaccine
Vaccine Information
References
Pye et al., 1997: Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine. 1997; 15(9); 1017-1023. [PubMed: 9261951].
P. falciparum MSP1 from transgenic mice with Freund's adjuvant
Vaccine Information
  • Vaccine Name: P. falciparum MSP1 from transgenic mice with Freund's adjuvant
  • Vaccine Ontology ID: VO_0000775
  • Type: Subunit vaccine
  • Antigen: the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1) (Stowers et al., 2002).
  • MSP-1 from P. falciparum gene engineering:
    • Type: Recombinant protein preparation
    • Description: Generated by transgenic mice (Stowers et al., 2002).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0000139
    • Description: The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).
  • Adjuvant:
    • VO ID: VO_0000142
    • Description: The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).
  • Preparation: Two strains of transgenic mice were generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1-42). One strain secretes an MSP1-42 with an amino acid sequence homologous to that of the FVO parasite line. In the other strain, an MSP1-42 where two putative N-linked glycosylation sites in the FVO sequence have been removed. Both forms of MSP142 were purified from whole milk to greater than 91% homogeneity at high yields (Stowers et al., 2002).
  • Virulence: None.
  • Description: It is likely for producing efficacious malarial vaccines in transgenic animals (Stowers et al., 2002).
References
Stowers et al., 2002: Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America. 2002 Jan 8; 99(1); 339-44. [PubMed: 11752405].
P. falciparum MSP3 Protein Subunit Vaccine
Vaccine Information
References
 
P. falciparum MSP4 with AFCo1 Adjuvant
Vaccine Information
References
 
P. falciparum pfCelTos protein vaccine
Vaccine Information
  • Vaccine Name: P. falciparum pfCelTos protein vaccine
  • Vaccine Ontology ID: VO_0004204
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • pfCelTOS gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001268
    • Description: Montanide ISA 720
  • Immunization Route: subcutaneous injection
References
 
P. falciparum Subunit SE36 Protein Vaccine
Vaccine Information
References
 
P. falciparum vaccine Combination B
Vaccine Information
  • Vaccine Name: P. falciparum vaccine Combination B
  • Tradename: Combination B
  • Vaccine Ontology ID: VO_0000740
  • Type: Subunit vaccine
  • Antigen: The vaccine Combination B contains three recombinant asexual blood-stage Plasmodium falciparum proteins: merozoite surface protein (MSP) 1, MSP2 and ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).
  • RESA gene engineering:
    • Type: Recombinant protein preparation
    • Description: The vaccine Combination B contains peptides from the ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).
    • Detailed Gene Information: Click Here.
  • MSP-1 from P. falciparum gene engineering:
    • Type: Recombinant protein preparation
    • Description: The vaccine Combination B contains MSP1 peptides (Genton et al., 2003).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001268
    • Description: Montanide ISA 720. It is an oil composition containing a natural metabolizable oil and a highly refined emulsifier from the mannide mono-oleate family (Genton et al., 2003).
  • Preparation: Combination B is a malaria vaccine that comprises recombinant P falciparum blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720 (Genton et al., 2003a). The three vaccine candidate antigens were produced by recombinant DNA technology. All three antigens were expressed in Escherichia coli with histidine tags to facilitate purification by nickel chelate chromatography. Two of the antigens, 190LCS.T3 (Ro 45-2067) and Ag1624 (Ro 46-2924), corresponded to parts of the well-characterized merozoite surface proteins MSP1 and MSP2, respectively. The MSP1 antigen was the 190L fragment from the K1 parasite line, comprising the relatively conserved blocks 3 & 4 of MSP1 fused with a universal T cell epitope derived from the circumsporozoite protein of P. falciparum. The MSP2 antigen corresponded to the near full-length MSP2 sequence of the 3D7 cloned line. Ag1505H (Ro 45-2164) consisted of the C-terminal 70% of RESA of the FCQ-27/PNG parasite line. All three antigens were supplied in separate vials at a concentration of 160 μg/ml of saline-Montanide ISA720 emulsion. Prior to use the three formulations were mixed and diluted with additional emulsion to give a dose of 15 μg of each antigen in a total volume of 0.55 ml (Genton et al., 2003).
  • Description: The "Combination B" vaccine resulted from a collaborative effort by the Papua New Guinea Institute for Medical Research along with the Australian Cooperative Research Center for Vaccine Technology in Queensland, The Walter and Eliza Hall Research Institute and the Swiss Tropical Institute (Girard et al., 2007). This vaccine has led to a considerable reduction of parasite density in the immunized children.
References
Genton et al., 2003: Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 Dec 8; 22(1); 30-41. [PubMed: 14604568].
Genton et al., 2003a: Genton B, Anders RF, Alpers MP, Reeder JC. The malaria vaccine development program in Papua New Guinea. Trends in parasitology. 2003 Jun; 19(6); 264-70. [PubMed: 12798084].
Girard et al., 2007: Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine. 2007 Feb 19; 25(9); 1567-80. [PubMed: 17045367].
P. vivax PVS25 with Montanide ISA-720
Vaccine Information
  • Vaccine Name: P. vivax PVS25 with Montanide ISA-720
  • Vaccine Ontology ID: VO_0000776
  • Type: Subunit vaccine
  • Antigen: P. vivax protein Pvs25 is the vaccine antigen. It is a protein composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).
  • Pvs25 gene engineering:
    • Type: Recombinant protein preparation
    • Description: Pvs25 was cloned and purified from yeast (Arevalo-Herrera et al., 2005).
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0001268
    • Description: Montanide ISA-720 an adjuvant suitable for human vaccination trials (Arevalo-Herrera et al., 2005).
  • Preparation: To produce a recombinant protein, Pvs25 was expressed in S. cerevisiae in a secreted form. Briefly, P. vivax genomic DNA from the Salvador I strain was used to amplify the gene fragment encoding the Pvs25 regions (Ala23-Leu195), which was inserted into the yeast episomal plasmid YEpRPEU-3 that encodes a secretory {alpha} factor containing a 6-His tail.12 Supernatants of fermentation were recovered by tangential microfiltration, concentrated by ultrafiltration, and extensively dialyzed. The retentate was incubated overnight at 4°C with Ni-nitrilotriacetic acid agarose. Proteins were purified by chromatography (Arevalo-Herrera et al., 2005).
  • Virulence: Not virulent.
References
Arevalo-Herrera et al., 2005: Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. The American journal of tropical medicine and hygiene. 2005 Nov; 73(5 Suppl); 32-7. [PubMed: 16291764].
P. yoelii TyCS-VLP Vaccine
Vaccine Information
References
Oliveira-Ferreira et al., 2000: Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine. 2000; 18(17); 1863-1869. [PubMed: 10699335].
PvCS/Montanide ISA-51
Vaccine Information
  • Vaccine Name: PvCS/Montanide ISA-51
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Antigen: PvCS: circumsporozoite protein of P. vivax. N+C: Two long synthetic peptides (LSP): the N-terminal (N) and C-terminal (C) regions; N+C+R: Three LSP: N-terminal, C-terminal, and the central repeats (R) regions. (Arévalo-Herrera et al., 2022)
  • CS from P. vivax gene engineering:
    • Type: Recombinant protein preparation
    • Description: N: N-term aa 20–96, C: C-term aa 301–372. R: VK210 (type I): first central repeat (aa 96–104) in tandem three times, collinearly linked to a universal T-cell epitope (ptt-30) derived from tetanus toxin. (Arévalo-Herrera et al., 2022)
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intramuscular injection (i.m.)
References
Arévalo-Herrera et al., 2022: Arévalo-Herrera M, Gaitán X, Larmat-Delgado M, Caicedo MA, Herrera SM, Henao-Giraldo J, Castellanos A, Devaud JC, Pannatier A, Oñate J, Corradin G, Herrera S. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nature communications. 2022; 13(1); 1603. [PubMed: 35338131].
Recombinant ABRA protein vaccine
Vaccine Information
  • Vaccine Name: Recombinant ABRA protein vaccine
  • Vaccine Ontology ID: VO_0000778
  • Type: Subunit vaccine
  • Host Species as Laboratory Animal Model: mouse
  • Antigen: The acidic basic repeat antigen (ABRA) of Plasmodium falciparum is a vaccine candidate against erythrocytic stages of malaria (Kushwaha et al., 2001).
  • ABRA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0000139
    • Description: Complete Freund's adjuvant (CFA) was used as the first adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA) (Kushwaha et al., 2001).
  • Preparation: The four fragments of ABRA, including N-terminal [ABRA (N); aa 24–369], middle [ABRA (M); aa 370–507], N-terminal + middle [ABRA (P); aa 24–507] and the C-terminal [ABRA (C); aa 508–743], were expressed as fusions with either maltose binding protein (MBP) or 6X histidine tag at their amino terminii using pMALc-2 vector from NEB (New England Biolabs, Beverly, MA, USA) or pQE30 vector (Qiagen GmbH, Germany), respectively. These recombinant proteins were purified to near homogeneity by affinity chromatography of the soluble fraction, concentrated, and the purity of the protein judged by SDS-PAGE.
References
Kushwaha et al., 2001: Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite immunology. 2001 Aug; 23(8); 435-44. [PubMed: 11489167].
RTS,S/AS02A
Vaccine Information
  • Vaccine Name: RTS,S/AS02A
  • Vaccine Ontology ID: VO_0000774
  • Type: Subunit vaccine
  • Status: Clinical trial
  • Antigen: RTS,S is the pre-erythrocyte sporozoite-stage Plasmodium falciparum antigen. It is a circumsporozoite surface protein (Alonso et al., 2004).
  • Adjuvant:
  • Preparation: RTS,S/AS02 is a pre-erythrocyte sporozoite-stage malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum RTS,S fused to HBsAg , incorporating a new adjuvant (AS02) (Bojang et al., 2001; Alonso et al., 2004).
References
Alonso et al., 2004: Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004 Oct 16-22; 364(9443); 1411-20. [PubMed: 15488216].
Bojang et al., 2001: Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001 Dec 8; 358(9297); 1927-34. [PubMed: 11747915].
S. neurona SAG1 Protein Vaccine
Vaccine Information
  • Vaccine Name: S. neurona SAG1 Protein Vaccine
  • Vaccine Ontology ID: VO_0004042
  • Type: Subunit vaccine
  • Status: Research
  • SAG1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
T. annulata Subunit SPAG-1 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. annulata Subunit SPAG-1 Protein Vaccine
  • Vaccine Ontology ID: VO_0011517
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: cow
  • spag-1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Intramuscular injection (i.m.)
References
 
T. annulata Tams1 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. annulata Tams1 Protein Vaccine
  • Vaccine Ontology ID: VO_0004181
  • Type: Subunit vaccine
  • Status: Research
  • TA17050 merozoite-piroplasm surface antigen Tams1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • VO ID: VO_0000757
    • Description: Immunostimulating complexes (ISCOMs) (d'Oliveira et al., 1997).
  • Immunization Route: Intramuscular injection (i.m.)
References
 
T. brucei Subunit p15 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. brucei Subunit p15 Protein Vaccine
  • Vaccine Ontology ID: VO_0011492
  • Type: Subunit vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: mouse
  • MAPP15 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Adjuvant:
  • Immunization Route: Subcutaneous
References
 
T. cruzi PAR1 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. cruzi PAR1 Protein Vaccine
  • Vaccine Ontology ID: VO_0001391
  • Type: Subunit vaccine
  • Status: Research
  • par1 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Adjuvant:
  • Immunization Route: Subcutaneous Injection
References
 
T. cruzi PAR2 Protein Vaccine
Vaccine Information
  • Vaccine Name: T. cruzi PAR2 Protein Vaccine
  • Vaccine Ontology ID: VO_0001392
  • Type: Subunit vaccine
  • Status: Research
  • Tc00.1047053434931.10 gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant:
  • Immunization Route: Subcutaneous Injection
References
 
T. parva Subunit p67 Protein Vaccine
Vaccine Information
References